SAN FRANCISCO, May 6 /PRNewswire-FirstCall/ -- Medizone (Pink Sheets: MZEI) is pleased to announce the commencement of the first in a series of trials designed to confirm that the Medizone AsepticSure(TM) Hospital Sterilization System can rapidly eliminate hospital-based bacterial pathogens known to be responsible for the growing number of deaths and serious infections currently plaguing the healthcare system world wide. Dr. Dick Zoutman, an internationally recognized expert in Medical Microbiology and hospital infections, is leading these trials. Medizone International's Director of Medical Affairs, Dr. Michael E. Shannon observed, "This is an exciting time for our medical engineering group. The equipment is superbly designed with full computer control of all test parameters and hence, we are confident that the entire series of studies will be GLP compliant. If these trials successfully demonstrate that our equipment and protocols are fully effective at eliminating the bacteria being tested, as we anticipate, the results will constitute a powerful signal to the health care community that a safe and inexpensive solution will soon be available to effectively address a problem which last year resulted in over 60,000 hospital acquired infectious disease deaths in North America alone."
"This project," added Dr. Zoutman, "has the potential of saving thousands of lives and hundreds of millions of dollars for hospital operating systems." Medizone expects to release the results of these first trials in June, following the filing of new patent applications.
Medizone International, Inc. is a research and development company engaged in developing its AsepticSuretechnology to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. If current trials continue to proceed successfully they will be followed by a hospital mock-up and then hospital beta testing of the production prototype. Initial sales are targeted to commence in the 4th quarter of this year.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations 800-953-3350 / web site: www.medizoneint.com
|SOURCE Medizone International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved